" DISCLAIMER: The ILO does not take responsibility for content presented on this web portal that is presented in any language other than English, which is the language used for the initial production and peer-review of original content. Certain statistics have not been updated since the production of the 4th edition of the Encyclopaedia (1998)."

Zaebst, Dennis

Zaebst, Dennis

Address: NIOSH R-44, 4676 Columbia Parkway, Cincinnati, Ohio 45226

Country: United States

Phone: 1 513 841-4459

Fax: 1 513 841-4470

E-mail: ddz1@cdc.gov

Education: MS, 1974, Ohio State Universtiy

Areas of interest: Research techniques; historical exposures; use of exposure data in epidemiological research; diesel exhaust exposures; agricultural health; indoor environmental quality; computers in industrial hygiene research



Part I. The Body
Part II. Health Care
Part III. Management & Policy
Part IV. Tools and Approaches
Part V. Psychosocial and Organizational Factors
Part VI. General Hazards
Part VII. The Environment
Part VIII. Accidents and Safety Management
Part IX. Chemicals
Part X. Industries Based on Biological Resources
Part XI. Industries Based on Natural Resources
Part XII. Chemical Industries
Chemical Processing
Oil and Natural Gas
Pharmaceutical Industry
Rubber Industry
Part XIII. Manufacturing Industries
Part XIV. Textile and Apparel Industries
Part XV. Transport Industries
Part XVI. Construction
Part XVII. Services and Trade
Part XVIII. Guides

Pharmaceutical Industry Additional Resources

Click the Button below to view additional resources for this topic.


Pharmaceutical Industry References

American Conference of Governmental Industrial Hygienists (ACGIH). 1995. Threshold Limit Values (TLVs) for Chemical Substances and Physical Agents and Biological Exposure Indices (BEIs). Cincinnati, OH: ACGIH.

Agius, R. 1989. Occupational exposure limits for therapeutic substances. Ann. Occ. Hyg. 33: 555-562.

Anastas, MY. 1984. Engineering and Other Health Hazard Controls in Oral Contraceptive Tablet-Making Operations. NIOSH, NTIS Pub. No. PB-85-220739. Cincinnati, OH: NIOSH.

Burton, DJ and E Shumnes. 1973. Health Hazard Evaluation USDHEW (NIOSH) Report 71-9-50. Cincinnati, OH: NIOSH.

Cole, G. 1990. Pharmaceutical Production Facilities: Design and Applications. Chichester, West Sussex: Ellis Horwood Ltd.

Crowl, D and J Louvar. 1990. Chemical Process Safety: Fundamentals with Applications. Englewood Cliffs, NJ: Prentice Hall.

Dunn, CW. 1940. Stilbestrol-induced gynecomastia in the male. JAMA 115:2263.

Environmental Protection Agency (EPA). 1993. Control of Volatile Organic Compound Emissions from Batch Processes. EPA453/R-93-017. Washington, DC: US EPA, Office of Air Quality.

—. 1995. Development Document for Proposed Effluent Limitations Guidelines and Standards for the Pharmaceutical Manufacturing Point Source Category. EPA-821-R-95-019. Washington, DC: US EPA, Office of Water.

Fisk, GH. 1950. Oestrogen absorption and toxicity in male workers in a chemical plant. Can Med Assoc J 62:285.

Fitzsimons, MP. 1944. Gynecomastia in Stilbestrol Workers. Brit J Ind Med 1:235.

Gambini, G, G Farine and G Arbosti. 1976. Estro-progestin syndrome in a worker engaged in the production of a contraceptive drug. Medicine Lavoro 67(2): 152-157.

Gennaro, A. 1990. Remington’s Pharmaceutical Sciences, 18th edition. Easton, PA: Mack Publishing Company.

Goldzieher, MA and JW Goldzieher. 1949. Toxic effects of percutaneously absorbed estrogens. JAMA 140:1156.

Hardman, JA Gilman and L Limbird. 1996. Goodman and Gilman’s The Pharmacologic Basis of Therapeutics. New York: McGraw Hill Co.

Hoover, RH. 1980. Association of exogenous estrogens and cancer in humans. In Estrogens in the Environment, edited by JA McLachlan. New York. Elsevier/North-Holland.

Houghton, DL and L Ritter. 1995. Organochlorine residues and risk of breast cancer. J Am College of Toxic 14(2):71-89.

International Labour Organization (ILO). 1983. Encyclopaedia of Occupational Health and Safety, 3rd edition. Geneva. ILO.

Katzenellenbogen, I. 1956. A dermato-endocrinological syndrome and problems connected with the production and use of stilbestrol. Harefuah 50:239.

Klavis, G. 1953. Casuistic report concerning deficiency symptoms of working with stilbestrol. J of Occup Med And Occup Safety 4:46-47.

Kroschwitz, J. (ed.). 1992. Kirk-Othmer Encyclopedia of Chemical Technology. New York: Wiley Interscience.

Medical Economics Co. 1995. Physician’s Desk Reference, 49th edition. Montvale, NJ: Medical Economics Co.

Meyer, CR, D Peteet and M. Harrington. 1978. Health Hazard Evaluation Determination. USDHEW (NIOSH) HE 77-75-494. Cincinnati, OH: NIOSH.

National Research Council. 1981. Prudent Practices for Handling Hazardous Chemicals in Laboratories. Washington, DC: National Academy Press.

Naumann, B, EV Sargent, BS Starkman, WJ Fraser, GT Becker and GD Kirk. 1996. Performance-based exposure control limits for pharmaceutical active ingredients Am Ind Hyg Assoc J 57: 33-42. 1996.

Pacynski, A, A Budzynska, S Przylecki and J Robaczynski. 1971. Hyperestrogenism in workers in a pharmaceutical establishment and their children and occupational disease. Polish Endocrinology 22:125.

Pagani, C. 1953. Hyperestrinic syndromes of exogenic origin. Annali di Ostetrica e Gynecologia 75:1173-1188.

Perry, R. 1984. Perry’s Chemical Engineers’ Handbook. McGraw- Hill Inc. New York, NY. 1984.

Reynolds, J. 1989. Martindale’s: The Extra Pharmacopoeias, 29th Edition. London: Pharmaceutical Press.

Sargent, E. and G Kirk. 1988. Establishing airborne exposure control limits in the pharmaceutical industry. Am Ind Hyg Assoc J 49:309-313.

Scarff, RW and CP Smith. 1942. Proliferative and other lesions of the male breast. Brit J Surg 29:393.

Spilker, B. 1994. Multinational Pharmaceutical Companies: Principles and Practices, 2nd edition. New York: Raven Press.

Stoppleman, MRH and RA van Valkenburg. 1955. Pigmentation and gynecomastia in children caused by hair lotion containing stilbestrol. Dutch J Med 99:2935-2936.

Suciu, I, V Lazar, I Visinescu, A Cocirla, O Zegreanu, A Sin, Z Lorintz, G Resu and A Papp. 1973. Concerning certain neuro-endocrine modifications during the preparation of acetoxyprogesterone. Arch mal prof méd trav sécur soc. 34:137-142.

Swarbick, J and J Boylan (eds.). 1996. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, Inc.

Tanaka, S and D Zaebst. 1984. Occupational Exposure to Estrogens: A Report of Two Pilot Medical and Industrial Hygiene Surveys. Cincinnati, OH: NIOSH.

Teichman, R, F Fallon and P Brandt-Rauf. 1988. Health effects on workers in the pharmaceutical industry: A review. J Soc Occ Med 38: 55-57.

Theodore, L and Y McGuinn. 1992. Pollution Prevention. New York: Van Nostrand Reinhold.

Watrous, RM. 1947. Health hazards of the pharmaceutical industry. Brit J Ind Med 4:111.

Watrous, RM and RT Olsen. 1959. Diethylstilbestrol absorption in industry: A test for early detection as an aid in prevention. Am Ind Hyg Assoc J 20:469.

Zaebst, D, S Tanaka and M Haring. 1980. Occupational exposure to estrogens: Problems and approaches. In Estrogens in the Environment, edited by JA McLachlan. New York: Elsevier/North-Holland.